The global COVID-19 count stands at 13,323,530 with 578,628 deaths being recorded as on July 15, and the figures are only shooting northwards with the spike continuing unabated in India as well, with around 29,000 new cases being recorded in the last 24 hours alone.
As the world grapples with the pandemic, all eyes are fixed on developments on the vaccine front. In a ray of hope, US-based Moderna may have a potential vaccine to prevent COVID -19. the tests have shown positive results in early-stage human trials and even India’s indigenous vaccine Zydus has begun human trials for a potential COVID-19 vaccine.
President Donald Trump also put out a tweet on Wednesday.
Great News on Vaccines!
— Donald J. Trump (@realDonaldTrump) July 15, 2020
US drugmaker Moderna’s potential vaccine to prevent COVID-19 produced a “robust” immune response in all 45 patients in its early stage human trial. This is an important landmark at a time when the world is grappling with the pandemic.
Addressing the same Dr. Anthony Fauci said “No matter how you slice this, this is good news,” Dr. Fauci is the U.S. A’s top infectious disease expert.
All 45 patients in the trial produced neutralizing antibodies which are believed to be important for building immunity. According to the findings published in the New England Journal of Medicine, they also provide promising data that the vaccine may give some protection against the coronavirus.
After two vaccinations, the vaccine elicited a “robust” immune response in all participants in all dose cohorts, Moderna said. The company said the levels of neutralizing antibodies in patients in the high dose group were fourfold higher than in recovered Covid-19 patients.
“These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and support the choice of 100 ugs in a prime and boost regimen as the optimal dose for the Phase 3 study,” Moderna’s chief medical officer, Tal Zaks, said in a statement. “We look forward to beginning our Phase 3 study of mRNA-1273 this month to demonstrate our vaccine’s ability to significantly reduce the risk of COVID-19 disease.”
In May, Moderna announced that phase I trial of its COVID-19 vaccine has shown positive early results. Moderna, based in Cambridge, Massachusetts had announced that the vaccine developed neutralizing antibodies to the virus at levels reaching or exceeding the levels seen in people who have naturally recovered from Covid-19, reported CNN. Earlier Tuesday, Moderna announced it would begin its late-stage trial for its vaccine on July 27.
India’s Zydus’s vaccine
Talking about India, Zydus had begun the human trials for a potential COVID-19 vaccine. Pharmaceutical major Zydus on Wednesday started human clinical trials of its plasmid DNA vaccine ZyCoV-D — a potential COVID-19 vaccine.
The adaptive phase one and two dose-escalation, the multi-centric study will assess the safety, tolerability, and immunogenicity of the vaccine. The human dosing of the vaccine marks a key milestone since the launching of the accelerated vaccine development program for COVID-19 in February, the company said.
“This is an all-important step in our fight against COVID-19,” said Chairman Pankaj R Patel. “We acknowledge the support of National Biopharma Mission, BIRAC, Department of Biotechnology and regulatory agencies ICMR and DGCI in the development of ZyCoV-D vaccine candidate,” he added.
Zydus will enroll over 1,000 subjects across multiple clinical study sites in India. The company has already manufactured clinical GMP batches of the vaccine candidate for clinical trials, it said in a statement. In the pre-clinical phase, the vaccine was found to generate a strong immune response in multiple animal species like mice, rats, guinea pigs, and rabbits.
(With Inputs from ANI)
Click here for Latest News updates and viral videos on our AI-powered smart news
For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us onInstagram